First Beijing Investment Ltd disclosed a new position in Legend Biotech (NASDAQ:LEGN), acquiring 2,296,335 shares in the first quarter, with the estimated trade valued at $43.78 million based on average quarterly pricing, according to a May 13, 2026, SEC filing.
Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.
-
Initiated new stake: 2,296,335 shares; estimated trade value $43.78 million (based on quarterly average price)
-
Quarter-end position value at $41.54 million, representing a net valuation change that includes price movements
-
Trade represented a 1.89% increase in 13F reportable assets under management
-
Post-trade: 2,296,335 shares held, valued at $41.54 million
-
Position accounts for 1.79% of 13F AUM, which places it outside the fund’s top five holdings
What happened
According to an SEC filing dated May 13, 2026, First Beijing Investment Ltd established a new stake in Legend Biotech, purchasing 2,296,335 shares. The estimated transaction value was $43.78 million, calculated using the average closing price for the first quarter. The quarter-end value of this position stood at $41.54 million, reflecting both purchase activity and share price movement during the period.
What else to know
-
New position: stake represents 1.79% of 13F reportable assets under management as of March 31, 2026
-
Top holdings after the filing:
-
NASDAQ: PDD: $832.68 million (35.9% of AUM)
-
NYSE: YMM: $747.01 million (32.2% of AUM)
-
NYSE: EDU: $509.40 million (22.0% of AUM)
-
NYSE: RLX: $132.29 million (5.7% of AUM)
-
NASDAQ: KSPI: $32.17 million (1.4% of AUM)
-
-
As of May 15, 2026, Legend Biotech shares were priced at $27.55, down 0.5% over the prior year, underperforming the S&P 500 by 25.7 percentage points
Company Overview
|
Metric |
Value |
|---|---|
|
Price (as of market close 2026-05-15) |
$27.55 |
|
Market Capitalization |
$5.08 billion |
|
Revenue (TTM) |
$1.14 billion |
|
Net Income (TTM) |
($250.98 million) |
Company Snapshot
-
Legend Biotech develops and commercializes novel cell therapies, including its lead CAR-T product candidate for multiple myeloma and a pipeline targeting various hematologic malignancies and solid tumors.
-
The company generates revenue primarily through the development and licensing of its cell therapy portfolio, leveraging strategic collaborations such as its agreement with Janssen Biotech for ciltacabtagene autoleucel.
-
Legend Biotech targets oncology patients, healthcare providers, and pharmaceutical partners in the United States, China, and international markets.
Legend Biotech Corporation is a clinical-stage biopharmaceutical company focused on advancing innovative cell therapies for cancer and related diseases. The company leverages proprietary CAR-T technologies and strategic partnerships to address high unmet medical needs in oncology. With a growing portfolio and international presence, Legend Biotech aims to establish a competitive position in the global biotechnology sector.
